Search Within

Hani Hassoun

Formats
  1. Meeting Abstract (206)
  2. Journal Article (79)
  3. Research Letter (7)
  4. Correspondence (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (298)
  2. Department of Medicine (298)
  3. Hematologic Malignancies, Division of (298)
  4. Myeloma (298)
  5. Survivorship Research (215)
  6. Bone Marrow Transplant (202)

More Groups

People
  1. Heather Landau (187)
  2. Sergio Giralt (166)
  3. Alexander Lesokhin (164)
  4. David Chung (132)
  5. Neha Korde (128)
  6. Sham Mailankody (125)

More People

Years
  1. 2024 (1)
  2. 2023 (37)
  3. 2022 (36)
  4. 2021 (21)
  5. 2020 (28)
  6. 2019 (24)

More Years

Publications
  1. Blood (120)
  2. Clinical Lymphoma, Myeloma and Leukemia (40)
  3. Journal of Clinical Oncology (24)
  4. Biology of Blood and Marrow Transplantation (19)
  5. Leukemia and Lymphoma (14)
  6. American Journal of Hematology (10)

More Publications

Publishers
  1. American Society of Hematology (123)
  2. Elsevier Inc. (62)
  3. American Society of Clinical Oncology (24)
  4. Taylor & Francis Group (21)
  5. Nature Publishing Group (17)
  6. John Wiley & Sons, Inc. (10)

More Publishers

Results (298)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy and safety of melflufen in patients with relapsed/refractory multiple myeloma refractory to daratumumab and/or pomalidomide: HORIZON (OP-106)
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; Rodriguez-Otero, P.; Norkin, M.; Blade, J.; Cavo, M.; Hassoun, H.; Leleu, X.; Alegre, A.; more...
    American Journal of Hematology (2019)

    Fulltext@MSK | Save
  • Cardiac ALL: Most unusual occurrence of lenalidomide-associated acute lymphoblastic leukemia with subsequent cardiac unvolvement
    Journal Article

    Sharma, N.; Hassoun, H.; Hatem, J.; Kouides, P.
    Cureus (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Moreb, J.; Blade, J.; Hassoun, H.; Cavo, M.; Alegre, A.; Mazumder, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Monoclonal gammopathy-associated thrombotic microangiopathy
    Journal Article

    Yui, J. C.; Garceau, D.; Jhaveri, K. D.; Wanchoo, R.; Bijol, V.; Glezerman, I.; Hassoun, H.; Dispenzieri, A.; Russell, S. J.; Leung, N.
    American Journal of Hematology (2019)

    Fulltext@MSK | Save
  • HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: Updated efficacy and safety
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Norkin, M.; BladeĢ, J.; Cavo, M.; Hassoun, H.; Leleu, X.; Alegre, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • OP-106 Horizon - Melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide: Updated results and first report on PFS
    Meeting Abstract

    Richardson, P.; Ocio, E.; Oriol, A.; Larocca, A.; Otero, P. R.; Moreb, J.; Blade, J.; Hassoun, H.; Cavo, M.; Alegre, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save